Analyse @AlbertBourla's tweets
Early data from our trial evaluating our Omicron BA.4/BA.5-adapted #COVID19 vaccine show increased neutralizing antibodies compared to our Original monovalent vaccine, suggesting it could potentially provide better protection against Omicron BA.4/BA.5: on.pfizer.com/3esniyR
I am incredibly proud to share that we have received Emergency Use Authorization from @US_FDA for our Omicron BA.4/BA.5-adapted #COVID19 vaccine for people aged 12 and older: on.pfizer.com/3wIpmIX